publication date: Dec. 11, 2020

NCI BSA approves 10 new and reissued concepts

By Alexandria Carolan

The NCI Board of Scientific Advisors has approved 10 new and reissued concepts.

NCI also asked BSA to endorse recompetition of the institute’s contract with the Frederick National Laboratory for Cancer Research.

While BSA voted unanimously to support NCI’s continuing affiliation with the facility, the board’s endorsement is not an approval of an RFP for a recompetition of the contract. A related story appears here.

The presentations are available here.

The following concepts were presented Dec. 12 at the joint meeting of the BSA and National Cancer Advisory Board.


Metabolic Dysregulation and Cancer Risk: A Transdisciplinary Approach to Obesity-Associated Cancer Research (New RFA/Coop. Agr.)

The goal of the RFA/Coop. Agr. is to support transdisciplinary research that will enhance the knowledge of the dynamics and underlying mechanisms that link obesity, metabolic dysregulation, and cancer risk.

The project will receive funding through the U01 grant.

The anticipated budget is $8 million per year, for a total of $40 million over five years. Six research projects, averaging $1.15 million per grant, are anticipated to cost $7 million per year. The coordinating center will cost $1 million per year.

The project includes two complementary funding announcements. The first will seek to fund multiple research project grants, and the other will seek to fund the coordinating center. These components, NCI staff on the project, will be part of a consortium governed by the steering committee that comprises NCI-funded PIs.

The RFA/Coop. Agr. was submitted by the Division … Continue reading NCI BSA approves 10 new and reissued concepts

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.